Production (Stage)
Capha Pharmaceuticals Inc.
FPSUF
$0.00
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -34.74% | -36.21% | -14.29% | 15.22% | 9.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.42% | -36.21% | -15.04% | 15.22% | 9.09% |
| Operating Income | 35.42% | 36.21% | 15.04% | -15.22% | -9.09% |
| Income Before Tax | 45.13% | 2.78% | 22.67% | -34.86% | 13.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.13% | 2.78% | 22.67% | -34.86% | 13.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.13% | 2.78% | 22.67% | -34.86% | 13.08% |
| EBIT | 35.42% | 36.21% | 15.04% | -15.22% | -9.09% |
| EBITDA | 34.74% | 36.21% | 14.29% | -15.22% | -9.20% |
| EPS Basic | 50.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Normalized Basic EPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS Diluted | 50.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Normalized Diluted EPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |